Indivior Pharmaceuticals (INDV) Cost of Revenue (2024 - 2026)

Indivior Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• On a quarterly basis, Cost of Revenue fell 9.09% year-over-year to $40.0 million in Q1 2026; TTM through Mar 2026 was $242.0 million, a 2.11% increase from a year earlier, with the FY2025 full-year figure at $246.0 million, up 6.49% from the prior year.
• Cost of Revenue eased to $40.0 million in Q1 2026 per INDV's latest filing, from $67.0 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $83.0 million in Q3 2025 and bottomed at $38.0 million in Q1 2024.
• The 3-year median for Cost of Revenue is $52.0 million (2025), against an average of $57.4 million.
• Biggest YoY gain for Cost of Revenue was 39.58% in 2025; the steepest drop was 34.18% in 2025.
• Year by year, Cost of Revenue stood at $48.0 million in 2024, then jumped by 39.58% to $67.0 million in 2025, then slumped by 40.3% to $40.0 million in 2026.
• Per Business Quant, the three latest INDV Cost of Revenue figures stand at $40.0 million (Q1 2026), $67.0 million (Q4 2025), and $83.0 million (Q3 2025).